SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Status:
Recruiting
Trial end date:
2031-02-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of SH-1028 tablets versus placebo in stage II-IIIB
non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor
(EGFR) mutations, following complete tumor resection, with or without adjuvant chemotherapy.